Source: [People's Daily Health Client] On June 16, Zhifei Bio announced on the Shenzhen Stock Exchange that the company recently received a report from its wholly-owned subsidiary Anhui Zhifei Longkoma Biopharmaceutical Co., Ltd. and learned that it developed a quadrivalent drug

2024/05/0509:14:32 hotcomm 1233

Source: [People's Daily Health Client]

html On June 16, Zhifei Biotech announced on Shenzhen Stock Exchange that the company recently received a report from its wholly-owned subsidiary Anhui Zhifei Longkoma Biopharmaceutical Co., Ltd. and learned about its research and development The quadrivalent influenza virus split vaccine obtained the phase III clinical trial summary report.

Source: [People's Daily Health Client] On June 16, Zhifei Bio announced on the Shenzhen Stock Exchange that the company recently received a report from its wholly-owned subsidiary Anhui Zhifei Longkoma Biopharmaceutical Co., Ltd. and learned that it developed a quadrivalent drug  - DayDayNews

project development. According to the announcement on the official website of Zhifei Biotechnology, the trial conclusion is that the vaccine has good immunogenicity and safety, fully meets the preset goals of the clinical trial, and is not inferior to the control vaccine in terms of safety and effectiveness. And it complies with the design requirements for effectiveness and safety evaluation in the "Technical Guiding Principles for Clinical Research of Seasonal Influenza Virus Vaccines".

National influenza monitoring shows that the positive rate of influenza virus testing in southern provinces continues to increase. According to news from the Hunan Provincial Center for Disease Control and Prevention on June 14, influenza sentinel surveillance in Hunan Province found that since mid-May, the percentage of influenza-like illness cases and the positive detection rate of influenza viruses in the province have shown an upward trend, indicating that summer influenza has entered. Fashion season. As of the date of the announcement, after checking the website of the National Medical Products Administration, 7 of the influenza vaccines officially approved for marketing in China are quadrivalent influenza virus split vaccines.

According to the 2021 annual report data, Zhifei Biotechnology’s independent products achieved revenue of 9.697 billion yuan. Zhifei Biotech stated that the clinical trial summary report of the quadrivalent influenza virus split vaccine will not have a significant impact on the company's recent performance. If the vaccine is approved for sale in the future, it will further enrich the company's products, enhance industry competitiveness, and strengthen the company's market status.

(Vaccine channel submission, industry communication email [email protected])

Editor: Zhu Xiaona

Proofreader: Lu Yang

This article comes from [People's Daily Health Client] and represents only the author's opinion. The National Party Media Information Public Platform provides information release and dissemination services.

ID:jrtt

hotcomm Category Latest News